| Nov 13 |
Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut
|
| Nov 13 |
Sanofi: Diverse Drug Portfolio And Future Pipeline, 4% Dividend Yield Looks Attractive
|
| Nov 13 |
Novavax Inc (NVAX) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial ...
|
| Nov 12 |
Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals
|
| Nov 12 |
Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
|
| Nov 11 |
Recordati SpA (RICFY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
|
| Nov 8 |
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
|
| Nov 7 |
Advent Mulls €5 Billion Sale of Generic Drugmaker Zentiva
|
| Nov 7 |
EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients
|
| Nov 6 |
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
|
